Table 2.
Relationships between blood hemoglobin (Hb) levels (g/L), erythrocyte mean corpuscular volume (MCV) levels (fL) and clinicopathological characteristics in the combined cohort.
| Variable (n) | Blood Hb, Mean (SD) | P value | Erythrocyte MCV, Mean (SD) | P value |
|---|---|---|---|---|
| All Patients (n = 356) | 126.6 (17.3) | 87.5 (6.7) | ||
| Age | ||||
| <65 (n = 130) | 129.5 (17.4) | 0.017 | 87.4 (7.1) | 0.908 |
| ≥65 (n = 226) | 124.9 (17.1) | 87.5 (6.4) | ||
| Sex | ||||
| Male (n = 190) | 130.8 (18.4) | <0.001 | 88.1 (7.0) | 0.063 |
| Female (n = 166) | 121.8 (14.7) | 86.8 (6.2) | ||
| Location of tumor | ||||
| Proximal colon (n = 123) | 116.4 (15.5) | <0.001 | 84.5 (7.0) | <0.001 |
| Distal colon (n = 73) | 125.1 (15.9) | 86.8 (6.4) | ||
| Rectum (n = 160) | 135.1 (14.8) | 90.1 (5.5) | ||
| Preoperative radiotherapy or chemoradiotherapy in rectal cancer patients | ||||
| No (n = 91) | 135.0 (16.0) | 0.986 | 89.9 (5.1) | 0.636 |
| Yes (n = 69) | 135.1 (13.3) | 90.3 (5.9) | ||
| WHO grade | ||||
| Grade 1 (n = 79) | 126.3 (17.6) | 0.023 | 87.4 (7.5) | 0.582 |
| Grade 2 (n = 229) | 128.0 (17.4) | 87.7 (6.3) | ||
| Grade 3 (n = 46) | 120.4 (15.7) | 85.6 (6.9) | ||
| TNM Stage | ||||
| Stage I (n = 81) | 132.4 (17.4) | <0.001 | 89.7 (6.2) | <0.001 |
| Stage II (n = 113) | 122.9 (17.1) | 85.9 (6.9) | ||
| Stage III (n = 115) | 128.0 (17.3) | 87.8 (6.6) | ||
| Stage IV (n = 46) | 122.3 (14.8) | 86.4 (6.2) | ||
| Primary tumor | ||||
| T1 (n = 16) | 136.4 (15.8) | <0.001 | 91.7 (5.7) | <0.001 |
| T2 (n = 89) | 131.5 (16.6) | 89.6 (6.1) | ||
| T3 (n = 218) | 125.1 (16.9) | 86.6 (6.8) | ||
| T4 (n = 32) | 119.0 (18.3) | 85.8 (5.8) | ||
| Lymph node metastasis | ||||
| N0 (n = 200) | 126.6 (17.7) | 0.135 | 87.5 (6.9) | 0.588 |
| N1 (n = 97) | 129.0 (16.8) | 87.9 (6.1) | ||
| N2 (n = 57) | 123.2 (16.7) | 86.7 (6.9) | ||
| Distant Metastasis | ||||
| M0 (n = 310) | 127.2 (17.6) | 0.072 | 87.6 (6.7) | 0.271 |
| M1 (n = 46) | 122.3 (14.8) | 86.4 (6.2) | ||
| Infiltrative growth pattern | ||||
| No (n = 278) | 127.1 (17.3) | 0.382 | 87.6 (6.5) | 0.475 |
| Yes (n = 77) | 125.1 (17.6) | 87.0 (7.4) | ||
| Lymphatic invasion | ||||
| No (n = 192) | 127.0 (17.4) | 0.698 | 87.8 (6.7) | 0.303 |
| Yes (n = 160) | 126.3 (17.4) | 87.1 (6.6) | ||
| Blood vessel invasion | ||||
| No (n = 293) | 126.9 (17.4) | 0.567 | 87.5 (6.8) | 0.867 |
| Yes (n = 59) | 125.5 (17.5) | 87.4 (6.0) | ||
| Mismatch repair (MMR) enzyme status | ||||
| MMR Proficient (n = 315) | 127.8 (17.0) | <0.001 | 85.1 (6.2) | 0.016 |
| MMR Deficient (n = 40) | 117.2 (17.2) | 87.8 (6.7) | ||
| BRAF VE1 immunohistochemistry | ||||
| Negative (n = 322) | 127.3 (17.5) | 0.010 | 87.5 (6.7) | 0.234 |
| Positive (n = 33) | 119.2 (14.8) | 86.1 (6.4) | ||
| Modified Glasgow Prognostic Score (mGPS) | ||||
| 0 (n = 269) | 128.8 (17.2) | <0.001 | 88.1 (6.8) | 0.018 |
| 1 (n = 63) | 120.0 (15.8) | 85.5 (6.2) | ||
| 2 (n = 8) | 105.5 (5.8) | 86.2 (2.7) | ||
| Mean corpuscular volume (MCV) | ||||
| <80 (n = 45) | 107.3 (11.0) | <0.001 | ||
| 80–100 (n = 306) | 129.4 (16.4) | |||
| >100 (n = 5) | 130.4 (14.0) | |||